Going straight to the angiography suite for suspected large vessel stroke
Compares going directly to the angiography suite with CT or MRI first in suspected stroke.
Plain-language title generated from the registry record
Registry title: Advancing Reperfusion Therapy for Ischemic Stroke: Direct Transfer to Angiography Suite for Patients With Suspected Large Vessel Occlusion
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Beijing Tiantan HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07460713
- Record updated
- 12 March 2026
- Original description
The investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MRI in patients with suspected large artery occlusive (LVO) within 6 hours of symptom onset.Read full original descriptionShow less
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Direct Transfer to Angiography Suite (DTAS) for Patients With Suspected Large Vessel Occlusion
The investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT/MRI in patients with suspected large artery occlusive (LVO) within 6 hours of symptom onset.
Inclusion: Age≥18 years old; Patients presenting with symptoms or signs suggestive of acute large vessel occlusion (LVO) stroke；; Randomization within 6 hours of symptom onset；; Baseline NIHSS score ≥10 points prior to randomization; Pre-stroke modified Rankin Scale (mRS) score ≤2; Written informed consent from patients or their legally authorized representatives.
Exclusion: Participation in other interventional clinical trials within the previous 3 months; Allergy to contrast agents; Clinical symptoms or signs suggestive of intracranial hemorrhage (e.g., severe headache, seizures, or signs of increased intracranial pressure); Seizure at stroke onset, postictal paralysis, or inability or unwillingness to cooperate due to epilepsy or other neurological or psychiatric disorders; Clinically unstable conditions requiring urgent life-support treatment; Any terminal illness such that the patient would not be expected to survive more than 1 year; Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study; Refusal of endovascular treatment；; Transferred patients (e.g., from centers without thrombectomy capability); Other standard contraindications to endovascular treatment; Pregnant women, nursing mothers, or women with a positive pregnancy test at admission; Unlikely to adhere to the trial protocol or follow-up.